2.33
0.09 (4.02%)
| Previous Close | 2.24 |
| Open | 2.29 |
| Volume | 509,460 |
| Avg. Volume (3M) | 1,687,201 |
| Market Cap | 148,137,968 |
| Price / Book | 6.50 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2026 |
| Diluted EPS (TTM) | -0.960 |
| Total Debt/Equity (MRQ) | 1.67% |
| Current Ratio (MRQ) | 3.00 |
| Operating Cash Flow (TTM) | -15.63 M |
| Levered Free Cash Flow (TTM) | -15.19 M |
| Return on Assets (TTM) | -90.68% |
| Return on Equity (TTM) | -332.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | TuHURA Biosciences, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.5 |
| Average | 0.38 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 41.96% |
| % Held by Institutions | 8.43% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suncoast Equity Management | 31 Dec 2025 | 104,409 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |